Liraglutide, a GLP-1 receptor agonist approved for diabetes and obesity, shows promise in treating NAFLD, the most prevalent chronic liver disease globally. Despite its therapeutic potential, the systematic molecular regulations underlying Liraglutide effects on NAFLD remain underexplored, indicatin...
ORGANISM(S): Mus musculus (Mouse)